Synexus Enters US market with Acquisition of Research Across America

Synexus, the world's leading Site Management Organisation, has strengthened its global reach with the acquisition of Research Across America (RAA) and its multiple dedicated research sites in the US.

The deal, for an undisclosed sum, will also give Synexus additional expertise in areas such as dermatology and generics.

Research Across America was founded in 1989 by Dr. Jeffrey Adelglass and has proven clinical trial expertise. Its board-certified physician investigators and professional research coordinators have managed nearly 2,000 clinical studies. RAA works with many major global pharmaceutical companies and contract research organisations.

Since being taken private in 2007 Synexus has enjoyed consistent growth using its targeted buy and build strategy. The company already owns 25 dedicated research sites across ten countries. The acquisition of RAA means Synexus can now offer customers access to over 79 million potential patients. The deal provides important capacity, US market expertise and therapeutic experience.

Speaking about the acquisition, Christophe Berthoux, Synexus CEO said: "Synexus already has a strong international footprint. This latest acquisition is important as it marks our entry into the US market, giving us truly global capability. We spent a great deal of time considering an appropriate partner and selected Research Across America as it has a number of synergies with the Synexus model."

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.